Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis

This study has been completed.
Information provided by (Responsible Party):
Napp Pharmaceuticals Limited Identifier:
First received: November 3, 2008
Last updated: September 22, 2011
Last verified: September 2011
Results First Received: July 14, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Osteoarthritis
Back Pain
Interventions: Drug: Oxycodone/Naloxone
Drug: Codeine/Paracetamol

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited in primary and secondary care in the UK from 6 Feb 2009 to 24 Mar 2010

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
3-7 day screening, following 7-14 day run-in and a 12 week double-blind treatment period.

Reporting Groups
Oxycodone/Naloxone Tablets (OXN) Oxycodone/Naloxone (OXN) tablets 5,10 and 20 mg
Codeine/Paracetamol Tablets Codeine/Paracetamol 15/500 and 30/500 mg

Participant Flow:   Overall Study
    Oxycodone/Naloxone Tablets (OXN)   Codeine/Paracetamol Tablets
STARTED   124   123 
COMPLETED   61   74 
NOT COMPLETED   63   49 
Adverse Event                32                20 
Lack of Efficacy                14                11 
Withdrawal by Subject                11                9 
Administrative                5                8 
Lost to Follow-up                1                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Oxycodone/Naloxone Tablets (OXN) Oxycodone/Naloxone (OXN) tablets 5,10 and 20 mg
Codeine/Paracetamol Tablets Codeine/Paracetamol 15/500 and 30/500 mg
Total Total of all reporting groups

Baseline Measures
   Oxycodone/Naloxone Tablets (OXN)   Codeine/Paracetamol Tablets   Total 
Overall Participants Analyzed 
[Units: Participants]
 124   123   247 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   66   70   136 
>=65 years   58   53   111 
[Units: Years]
Mean (Standard Deviation)
 64.3  (10.53)   63.9  (10.97)   64.1  (10.73) 
[Units: Participants]
Female   77   81   158 
Male   47   42   89 
Region of Enrollment 
[Units: Participants]
United Kingdom   124   123   247 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Average Daily Pain Score Box Scale-11 (BS-11) Recorded at Week 12 (Average Pain Over Last 24 Hours)   [ Time Frame: Average daily pain over last 24 hours (at Week 12) ]

2.  Secondary:   Number of Intakes of Rescue Medication (Ibuprofen) Between Visit 8 and Visit 9 for the 2 Groups.   [ Time Frame: Between visit 8 and 9 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Director of Medical Affairs
Organization: Napp Pharmaceuticals Ltd
phone: 01223 424444

Responsible Party: Napp Pharmaceuticals Limited Identifier: NCT00784810     History of Changes
Other Study ID Numbers: OXN4502 (2008-002426-10)
Study First Received: November 3, 2008
Results First Received: July 14, 2011
Last Updated: September 22, 2011